The Preclinical Therapeutics Core (Core) provides in vivo services to UCSF Helen Diller Family Comprehensive Cancer Center (Center) investigators. Offering a variety of tumor engraftment-based cancer models for use in preclinical oncology trials, the Core provides a complete set of services that include consultation regarding experimental design, tumor cell culture and implantation in mice, administration of experimental agents, monitoring of tumor burden and response to therapy, and interpretation of study results. The Core maintains a cryorepository of commonly used human cancer cell lines derived from multiple tumor types along with data regarding their in vivo growth characteristics, as well as a collection of patient-derived tumor xenograft models. The Core's offerings also include pharmacological analysis and optimization of novel agents such as compound formulation, pharmacokinetics (PK), pharmacodynamics (PD), and safety-toxicity analyses. The Core is also a resource of expertise in small animal survival surgery, and is available to provide training in these techniques on a recharge basis. Although the Core primarily functions to test experimental anti-cancer agents in vivo, it also provides animal models of human cancer for use in novel diagnostic, tumor imaging, and basic mechanistic research. The Core oversees, maintains, and provides as a service a number of small animal imaging technologies housed within the barrier facility. The availability of centralized cell and animal resources, together with personnel with expertise in conducting preclinical studies, ensures appropriate experimental design and reproducibility, compliance with local and federal regulatory guidelines for tumor-bearing animals, and maximum resource utilization through coordinated animal purchasing and housing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-16
Application #
8693947
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$263,196
Indirect Cost
$96,533
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
John, Constance M; Phillips, Nancy J; Din, Richard et al. (2016) Lipooligosaccharide Structures of Invasive and Carrier Isolates of Neisseria meningitidis Are Correlated with Pathogenicity and Carriage. J Biol Chem 291:3224-38
Shatsky, Maxim; Dong, Ming; Liu, Haichuan et al. (2016) Quantitative Tagless Copurification: A Method to Validate and Identify Protein-Protein Interactions. Mol Cell Proteomics 15:2186-202
Nordström, Tobias; Van Blarigan, Erin L; Ngo, Vy et al. (2016) Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate 76:339-48
Bulut-Karslioglu, Aydan; Biechele, Steffen; Jin, Hu et al. (2016) Inhibition of mTOR induces a paused pluripotent state. Nature 540:119-123
Akutagawa, J; Huang, T Q; Epstein, I et al. (2016) Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia 30:1335-43
Baeza-Raja, Bernat; Sachs, Benjamin D; Li, Pingping et al. (2016) p75 Neurotrophin Receptor Regulates Energy Balance in Obesity. Cell Rep 14:255-68
Ko, Andrew H; Bekaii-Saab, Tanios; Van Ziffle, Jessica et al. (2016) A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res 22:61-8
Nosbaum, Audrey; Prevel, Nicolas; Truong, Hong-An et al. (2016) Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing. J Immunol 196:2010-4
Phan, An T; Fernandez, Samantha G; Somberg, Jessica J et al. (2016) Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels. Biochem Biophys Res Commun 474:71-5
Chang, Matthew T; Asthana, Saurabh; Gao, Sizhi Paul et al. (2016) Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 34:155-63

Showing the most recent 10 out of 135 publications